Date:5/17/2010

3,338,193 682,145 Liabilities assumed from reorganization (95,384) (1,164,323) Taxes payable (6,308,625) 5,107,831 Net cash provided by operating activities 8,484,399 41,078,364 CASH FLOWS FROM INVESTING ACTIVITIES: Cash used in acquisition -- (8,581,970) Proceeds from sale of marketable securities 531,750 167,623 Purchase of equipment (76,977) (130,814) Purchase of land use right (16,975,633) -- Net cash used in investing activities (16,520,860) (8,545,161) CASH FLOWS FROM FINANCING ACTIVITIES: Change in restricted cash (4,186,572) 4,149,305 Proceeds from bank loans 2,199,600 2,196,750 Payments for bank loans (2,199,600) (2,782,550) Proceeds from notes payable 19,173,180 7,009,097 Principal payments on notes payable (14,986,608) (9,161,912) Net cash (used in) provided by financing activities -- 1,410,690 EFFECTS OF EXCHANGE RATE CHANGE IN CASH 134,826 198,836 INCREASE (DECREASE) IN CASH (7,901,635) 34,142,729 CASH, beginning 104,366,117 48,195,798 CASH, ending $ 96,464,482 $ 82,338,527 SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid for Interest $ 393,111 $ 1,130,837 Cash paid for Income taxes $ 2,631,495 $ 4,883,039 Non-cash investing and financing activities: Common stock issued to acquire
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related medicine technology :

1. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
2. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
3. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
4. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
5. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
7. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
8. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
9. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
10. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET
11. Jazz Pharmaceuticals Announces Public Offering of Common Stock